COMPASS Pathways appoints Kabir Nath as CEO effective August 1, 2022; George Goldsmith becomes Executive Chairman
COMPASS Pathways plc
Kabir Nath appointed CEO, effective August 1, 2022; he brings 30 years biopharma experience, most recently at Otsuka and Bristol-Myers Squibb.
George Goldsmith transitions to Executive Chairman from Aug 1 to Dec 31, 2022, then remains Chairman; his base salary is £346,800 with 55% target bonus.
Nath receives $580,000 base salary, 60% target bonus, 600,000 stock options and 50,000 RSUs vesting over four years.
Nath also gets a £12,000/month housing stipend through Aug 2023, $5,000 legal fees, and $250,000 relocation payment.
Goldsmith's pro-rated 2022 bonus reflects reduced salary from August; employment ends Dec 31, 2022 per amended agreement.
On July 19, 2022, COMPASS Pathways plc (the “Company”) announced that its board of directors has appointed Kabir Nath as the Company’s chief executive officer effective August 1, 2022.
Mr. Nath will also be appointed as a member of the board of directors as a Class II director effective as of August 1, 2022.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Kabir Nath was appointed as chief executive officer at COMPASS Pathways plc.
Action
appointed
Role
chief executive officer
Exact text from the filing
On July 19, 2022, COMPASS Pathways plc (the “Company”) announced that its board of directors has appointed Kabir Nath as the Company’s chief executive officer effective August 1, 2022.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.